Analysts fell to the sidelines weighing in on Sumitomo Dainippon Pharma Co (DNPUF – Research Report) and Sanofi (SNYNF – Research Report) with ...
A new international biotech – Sumitovant Biopharma – has been created after Sumitomo Dainippon’s strategic alliance with Roivant Sciences came to fruition as 2019 drew to a close.
日经225指数 中表现最好的股票为Sumitomo Dainippon Pharma Co Ltd (TYO: 4506 ),上涨9.72%(69.00点),收盘报价为779.00。同时,住友电工 (TYO: 5802 ...
日经225指数 中表现最好的股票为Sumitomo Dainippon Pharma Co Ltd (TYO: 4506 ),上涨16.39%(100.00点),收盘报价为710.00。同时,Konami Corp. (TYO: 9766 ...
Ltd. The company has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd.
来自MSN11 个月
日本股市上涨;截至收盘日经225指数上涨2.19%Sumitomo Dainippon Pharma Co Ltd (TYO:4506)下跌2.51%(9.00点),收于349.00;CyberAgent Inc (TYO:4751)收盘时跌2.33%(24.50点),报价1,029.00。 东京证券交易所0只个股 ...
Sumitomo already held around 52% of the company ahead of the new offer – which values Myovant at around $2.9 billion – and is spending $1.7 billion to gain 100% ownership of its shares.
当前正在显示可能无法访问的结果。
隐藏无法访问的结果